Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Keeps Buy Rating at BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at BTIG Research in a report released on Wednesday, Benzinga reports. They presently have a $14.00 price target on the stock. BTIG Research's target price indicates a potential upside of 426.32% from the company's current price.

Other equities research analysts have also recently issued reports about the stock. BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. William Blair initiated coverage on Perspective Therapeutics in a report on Friday, September 18th. They issued an "outperform" rating on the stock. Piper Sandler cut their target price on Perspective Therapeutics from $16.00 to $14.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Bank of America cut their target price on Perspective Therapeutics from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, August 14th. Finally, Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Perspective Therapeutics has a consensus rating of "Buy" and an average price target of $11.50.

Perspective Therapeutics Stock Performance

CATX stock traded down $0.05 during midday trading on Wednesday, hitting $2.66. The company's stock had a trading volume of 1,104,542 shares, compared to its average volume of 2,239,350. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The firm has a 50-day simple moving average of $2.94 and a 200-day simple moving average of $3.40.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03. Perspective Therapeutics had a negative net margin of 28,467.97% and a negative return on equity of 41.92%. The company had revenue of $0.08 million during the quarter, compared to analysts' expectations of $0.09 million. On average, research analysts predict that Perspective Therapeutics will post -0.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Commodore Capital LP acquired a new stake in Perspective Therapeutics during the 1st quarter worth $26,424,000. Avidity Partners Management LP raised its stake in Perspective Therapeutics by 88.4% during the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock worth $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Affinity Asset Advisors LLC raised its stake in Perspective Therapeutics by 954.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company's stock worth $13,196,000 after acquiring an additional 2,864,582 shares in the last quarter. Spruce Street Capital LP acquired a new stake in Perspective Therapeutics during the 1st quarter worth $10,955,000. Finally, Yu Fan acquired a new stake in Perspective Therapeutics during the 1st quarter worth $4,401,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company's approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective's proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.